← All trials
NCT05885906
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 24, 2023
- Primary completion
- Oct 31, 2023
- Completion date
- Mar 31, 2024
- First posted
- Jun 2, 2023
- Last posted
- Sep 14, 2023
- Enrollment
- 45
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ain Shams UniversityLead sponsor
- Ain Shams UniversityReponsible party - principal investigator
- Ain Shams UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.